About Mangeet Kaur Bouns
Mangeet’s keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet’s looks to help retail investors understand the underlying factors before making investment decisions.
She earned a bachelor's degree in finance from BI Norwegian Business School.
Recent Articles By Mangeet Kaur Bouns
Keep an Eye on These 3 Promising Air Defense Stocks
The aerospace and defense (A&D) industry’s outlook appears promising, thanks to solid demand for air travel, escalating geopolitical instability, and rapid technological adoption. Amid this backdrop, quality air defense stocks Air Lease (AL), MSA Safety (MSA), and CAE (CAE) could be ideal watchlist additions now. Continue Reading…
3 Luxury Stock Buys for Stable Profits
Rising disposable income, changing customer priorities and digital advancements are offering ample growth opportunities to the luxury fashion stocks. Thus, it could be wise to invest in quality luxury fashion stocks Caleres (CAL), Tapestry (TPR), and PVH (PVH). Continue Reading…
Buy, Sell, or Hold: Analyzing 3 Specialty Retailer Stocks
With solid consumer spending, changing customer preferences, proliferation of e-commerce platforms, and rapid digitalization, the specialty retailer industry is well-poised for significant growth. Amid this, let’s determine if you should buy, sell, or hold specialty retailer stocks: GameStop (GME), ODP Corporation (ODP), and Aeon (AONNY). Read on…
3 Internet Gems Driving Profits for Investors
Increased internet penetration has been a catalyst for digital transformation across various sectors, creating lucrative opportunities for companies providing internet-based services. Hence, it could be wise to invest in quality internet stocks Despegar.com (DESP), D-Market Elektronik Hizmetler (HEPS), and Travelzoo (TZOO) for potential profits. Keep reading…
Elite 4 Biotech Stocks to Buy Now for Explosive Returns
With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on…
Wall Street's Top 3 Software Stocks Crushing the Competition
Robust software demand among individuals and businesses and numerous technological breakthroughs have opened lucrative growth opportunities for software providers. Thus, it could be wise to invest in Wall Street’s top software stocks, F5 (FFIV), DocuSign (DOCU), and Trend Micro (TMICY), which are crushing the competition. Continue Reading…
3 B-Rated Foreign Bank Stocks to Consider
The U.S. banking sector continues to face challenges, including rising deposit costs in a high-rate environment, credit rating downgrades, and risk of defaults in commercial real estate (CRE) lending. Hence, it could be wise to look beyond borders and add quality foreign bank stocks Banco Macro (BMA), Banco Santander (SAN), and Barclays (BCS) to your portfolio. These stocks are rated B (Buy) in our proprietary rating system. Read on…
Why Investors Are Flocking to These 2 Medical Stocks
Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more…
Are These 3 Coal Stocks Right for Your Investment Strategy?
Despite rising environmental concerns and the emergence of renewable energy alternatives, coal continues to be a desirable choice to satisfy the growing global energy demand because of its scalability and affordability. Thus, let’s determine if coal stocks Yankuang Energy (YZCAY), Warrior Met Coal (HCC), and CONSOL Energy (CEIX) fit into your investment strategy. Read on...